tt777com| Kexing Pharmaceutical (688136.SH): Obtained GB08 Drug Clinical Trial Approval Notice for Injection

Gelonghui May 24 丨 Kexing Pharmaceutical (688136tt777com.SH) Announcementtt777com, Shenzhen Kexing Pharmaceutical Co., Ltd., a wholly-owned subsidiary, received the "Drug Clinical Trial Approval Notice" issued by the State Food and Drug Administrationtt777com, the State Food and Drug Administration approved Shenzhen Kexing to carry out the clinical trial of "GB08 Injection". GB08 injection is the company's first independently developed Class I innovative drug. It is an Fc fusion protein long-acting growth hormone independently developed by the company based on the needs of clinical patients and based on childhood growth hormone deficiency.